DR. DARRYL CRAIG ZELDIN, MD
Osteopathic Medicine at Fulton St, Durham, NC

6693130, Feb 17, 2004

Dec 23, 2002

10/328495

Deanna L. Kroetz - San Francisco CA
Darryl C. Zeldin - Chapel Hill NC
Bruce D. Hammock - Davis CA
Christophe Morisseau - West Sacramento CA

Regents of the University of California - Oakland CA

A61K 31335

514475, 435 792

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by wherein R is alkyl or aryl, the compound is trans-across the epoxide ring, OX is a carbonyl ( O) or hydroxy group (OH) and R′ is a H, alkyl or aryl group. The invention further provides methods of identifying patients at increased risk for hypertension, comprising assaying for epoxide hydrolase activity in a urine sample from the patient. In particular, the assays comprise determining the amount of dihydroxyeicosatrienoic acids (DHETs), determining the amount of epoxyeicosatrienoic acids (EETs) in said sample, or determining the amount of both DHETs and EETs in said sample.

6531506, Mar 11, 2003

Nov 21, 2000

09/721261

Deanna L. Kroetz - San Francisco CA
Darryl C. Zeldin - Chapel Hill NC
Bruce D. Hammock - Davis CA
Christophe Morisseau - West Sacramento CA

Regents of the University of California - Oakland CA

A61K 31335

514475, 514529, 514551, 514625, 514613, 514631, 514596, 514588, 514595

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R -R is hydrogen, R is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R and R is each independently C -C substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

2011024, Oct 6, 2011

May 20, 2011

13/113028

Deanna L. Kroetz - San Francisco CA, US
Darryl C. Zeldin - Chapel Hill NC, US
Bruce D. Hammock - Davis CA, US
Christophe Morisseau - Sacramento CA, US

The Regents of the University of California - Oakland CA
GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUM - Rockville MD

A61K 31/7088, A61P 9/12, C12N 9/96, C12Q 1/34

514 44 R, 435188, 435 18

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R-Ris hydrogen, Ris hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, Ris hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, Rand Ris each independently C-Csubstituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

2005028, Dec 22, 2005

Jul 25, 2005

11/189964

Deanna Kroetz - San Francisco CA, US
Darryl Zeldin - Chapel Hill NC, US
Bruce Hammock - Davis CA, US
Christophe Morisseau - Sacramento CA, US

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Office of Technology Transfer - Oakland CA
THE GOVERNMENT OF THE U.S., as represented by the Secretary of the Dept. of Health & Human Services - Rockville MD

A61K048/00, A61K031/336, A61K031/325

514044000, 514475000, 514476000

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R—Ris hydrogen, Ris hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, Ris hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, Rand Ris each independently C-Csubstituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

2004009, May 13, 2004

Oct 27, 2003

10/694641

Deanna Kroetz - San Francisco CA, US
Darryl Zeldin - Chapel Hill NC, US
Bruce Hammock - Davis CA, US
Christophe Morisseau - Sacramento CA, US

A61K048/00, A61K031/66, A61K031/335, A61K031/325, A61K031/17

514/114000, 514/475000, 514/044000, 514/478000, 514/580000, 514/588000

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R-Ris hydrogen, Ris hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, Ris hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, Rand Ris each independently C-Csubstituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

6916843, Jul 12, 2005

Aug 9, 2000

09/634369

James K. Liao - Weston MA, US
Darryl Zeldin - Chapel Hill NC, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K031/335

514449, 514475

Epoxyeicosatrienoic acids (EETs) are products of cytocrome P450 epoxygenases that have vasodilatory properties similar to endotheilum-derived hyperpolarizing factor (EDHF). The cytochrome P450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion molecule expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-κB and IκB kinase (IKK). The inhibitory effects of EETs were independent of their membrane hyporpolarizing effects suggesting that these molecules play an important non-vasodilatory role in vascular inflammation.

8008463, Aug 30, 2011

Apr 18, 2003

10/511362

Perry J. Blackshear - Chapel Hill NC, US
Deborah J. Stumpo - Durham NC, US
Darryl C. Zeldin - Chapel Hill NC, US
Joan P. Graves - Raleigh NC, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

C07H 21/04, C12H 15/63, C12Q 1/68, A01K 67/00

536 235, 435 6, 4353201, 435455

The present disclosure relates to RFX4_v3 protein and nucleic acids encoding the RFX4_v3 protein. The present disclosure provides non-human transgenic animals with altered RFX4_v3 genes, and provides assays for the detection of RFX4_v3 and RFX4_v3 polymorphisms associated with disease states. The present disclosure additionally provides methods of determining a subjects' risk of developing congenital hydrocephalus, and treating or inhibiting its development.